Abstract 93P
Background
Circulating cell-free DNA (cfDNA) may be used for monitoring response to systemic treatment in patients with advanced carcinomas. Tumor-derived cfDNA is characterized by a shift of fragment sizes. The aim of the study was to evaluate longitudinally the changes in cfDNA fragmentation profile and correlate it with disease progression in non-small cell lung cancer (NSCLC) patients receiving anticancer systemic therapy.
Methods
We recruited 14 patients aged 36 - 72 years at diagnosis with advanced stage IIIb/IV NSCLC and performance status 0-2 at diagnosis. All patients were initially tested on PD-L1 expression as well as on mutations in the EGFR and the ALK genes. Patients with positive PD-L1 expression (n=3) received immunotherapy pembrolizumab as the first-line therapy, those with mutations in the EGFR gene (n=3) received tyrosine kinase inhibitor - gefitinib, one ALK-positive patient received alectinib, while other patients received standard chemotherapy - Carboplatin/Etoposide (n=3) or Carboplatin/Paclitaxel (n=4). Consecutive plasma samples were collected at diagnosis, during systemic treatment and after termination of the therapy. cfDNA was extracted from 0.5 mL of plasma using magnetic-based MagMax cfDNA extraction kit, and quantified using Qubit HS dsDNA assay and ddPCR. Contamination with genomic DNA was determined using a B-cell-specific ddPCR assay. Fragment size distribution of cfDNA was determined by Agilent Bioanalyzer HS dsDNA assay.
Results
Concentrations of cfDNA measured by Qubit (∼14.3 ng/mL of plasma) showed good correlation to the absolute quantification determined by ddPCR (∼13.22 ng/mL of plasma). In a 38% of samples there was small contamination by peripheral blood cells gDNA. Besides expected fraction of cfDNA (168 bp mode) observed in all samples, we observed in 48% of samples an ultra-short fraction of cfDNA (50bp mode).
Conclusions
Application of magnetic-based cfDNA extraction method allowed us to detect an ultra-short cfDNA fraction, previously unrecognized in lung cancer patients. Studies to correlate it to progression-free survival are ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institute for Oncology and Radiology of Serbia.
Funding
The Science Fund of the Republic of Serbia (PROMIS/2020/6060876).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
85P - Stereotactic radiotherapy improves disease control in oligoprogressive patients included in early clinical trials
Presenter: Antoine Mavrikios
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Validation of the Gustave Roussy Immune (GRIm) score in patients treated with bispecific CD3 T cell engagers in phase I clinical trials
Presenter: Noé Herbel
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Clinical features and genetic profile of MDM2-altered solid tumors
Presenter: Julia Tejerina-Peces
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluation of trending drug targets and technologies in current drug development
Presenter: Matteo Repetto
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Impact of metformin on glucocorticoid-induced changes in systemic metabolism in patients with brain metastases from solid malignancies
Presenter: Filippo Guglielmo Maria De Braud
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Effect of age on safety and efficacy of novel cancer drugs investigated in early phase clinical trials
Presenter: Jacopo Uliano
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - Molecular predictors of response to the therapy with mitotane in adrenocortical cancer
Presenter: Erika Porubayeva
Session: Cocktail & Poster Display session
Resources:
Abstract
94P - Targeted therapy in pediatric acute myeloid leukemia: An unmet need
Presenter: Banda Teja
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Anticancer activity of Inula recemosa root extract in human liver cancer cell line by attenuation of OCT4/Sox2 axis
Presenter: Tania Ghosh(Sarkar)
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - The Hammersmith score optimises patient selection and predicts for overall survival in early-phase cancer trial participants independent of tumour burden
Presenter: James Korolewicz
Session: Cocktail & Poster Display session
Resources:
Abstract